Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.3% - What's Next?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) fell 3.3% during trading on Thursday . The company traded as low as $6.78 and last traded at $6.78. 1,108,949 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 5,763,784 shares. The stock had previously closed at $7.01.

Analyst Ratings Changes

RXRX has been the topic of a number of research analyst reports. Needham & Company LLC lowered their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating on the stock in a research report on Wednesday, September 4th. KeyCorp lowered their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating on the stock in a report on Thursday, July 11th. Jefferies Financial Group cut their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a report on Tuesday, September 3rd. Finally, Leerink Partners lowered their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a report on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Down 6.6 %

The business's 50-day moving average price is $6.70 and its 200-day moving average price is $7.81. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company had revenue of $14.42 million during the quarter, compared to analysts' expectations of $11.96 million. During the same quarter in the previous year, the company earned ($0.38) EPS. The business's quarterly revenue was up 30.9% compared to the same quarter last year. On average, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total transaction of $76,351.49. Following the transaction, the director now owns 7,089,007 shares of the company's stock, valued at $47,283,676.69. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the sale, the chief operating officer now owns 535,457 shares in the company, valued at $4,353,265.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the firm's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total value of $76,351.49. Following the transaction, the director now owns 7,089,007 shares of the company's stock, valued at approximately $47,283,676.69. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 213,129 shares of company stock valued at $1,430,004. 15.75% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Green Alpha Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 2.9% in the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company's stock worth $427,000 after buying an additional 1,800 shares in the last quarter. Wedmont Private Capital increased its stake in Recursion Pharmaceuticals by 11.8% during the first quarter. Wedmont Private Capital now owns 18,943 shares of the company's stock worth $172,000 after acquiring an additional 2,000 shares during the last quarter. Interchange Capital Partners LLC lifted its stake in shares of Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company's stock valued at $268,000 after purchasing an additional 2,349 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after purchasing an additional 2,459 shares during the period. Finally, Benjamin F. Edwards & Company Inc. bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at approximately $26,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.